RE:RE:stockman, of course they pay only if FDA gives theThe $17 M was for the sale of the two blood collection centers - not for Ryplazim. At this moment, Kedrion has paid ZERO for Ryplazim, and will ONLY pay t he $5 M if they find the FDA approves Ryplazim so they will get a revenue source in Ryplazim without risk, plus a free approx $30 M gift on the voucher -- FOR FREE. SALP is giving away the LIMINAL store!! Now they are starting to undercut the 4050 side of the company. Watch over the next months as this accelerates. Even if something happens here, itt will take many years of trials without any revenue for a long time! Except for a short catalyst for the approx $70 M voucher, if the FDA approves it, they are in deep doo doo formany years without any revenue stream. Investors won't touch this with a ten foot pole.